{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:04:27Z","timestamp":1785769467582,"version":"3.56.0"},"reference-count":125,"publisher":"Bentham Science Publishers Ltd.","issue":"8","funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["Grant no. 23-69-10035"],"award-info":[{"award-number":["Grant no. 23-69-10035"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Hepatobiliary system cancers have demonstrated an increasing incidence rate in the\npast years. Without the presence of early symptoms, the majority of such cancers manifest with a\nset of similar symptoms, such as cholestasis resulting in posthepatic icterus. Differential diagnosis\nof hepatobiliary cancers is required for the therapy selection, however, the similarity of the symptoms\ncomplicates diagnostics. Thus, the search for molecular markers is of high interest for such\npatients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Cholangiocarcinoma (CCA) is characterized by a poor prognosis due to a low resectability rate,\nwhich occurs because this disease is frequently beyond the limits of surgical therapy at the time of\ndiagnosis. The CCA is diagnosed by the combination of clinical\/biochemical features, radiological\nmethods, and non-specific serum tumor biomarkers, although invasive examination is still needed.\nThe main disadvantage is limited specificity and sensitivity, which complicates early diagnostics.\nTherefore, prognostic and predictive biomarkers are still lacking and urgently needed for early diagnosis.\nIn contrast to serum, bile is more accessible to identify biliary disease due to its simpler\ncomposition. Moreover, bile can contain higher concentrations of tumor biomarkers due to its direct\ncontact with the tumor. It is known that the composition of the main bile component - bile\nacids, may vary during different diseases of the biliary tract.\nThis review summarizes the recent developments in the current research on the diagnostic biomarkers\nfor CCA in serum and bile and provides an overview of the methods of bile acids analysis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115680266290367240130054142","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T06:36:46Z","timestamp":1706855806000},"page":"722-736","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular Biomarkers in Cholangiocarcinoma: Focus on Bile"],"prefix":"10.2174","volume":"24","author":[{"given":"Andrey D.","family":"Dolbnya","sequence":"first","affiliation":[{"name":"Siberian State Medical University, Tomsk, 634050, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor A.","family":"Popov","sequence":"additional","affiliation":[{"name":"Siberian State Medical University, Tomsk, 634050, Russian Federation"},{"name":"Moscow Institute of Physics and Technology,\nDolgoprudny, 141701, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-3457","authenticated-orcid":true,"given":"Stanislav I.","family":"Pekov","sequence":"additional","affiliation":[{"name":"Siberian State Medical University, Tomsk, 634050, Russian Federation"},{"name":"Moscow Institute of Physics and Technology,\nDolgoprudny, 141701, Russian Federation"},{"name":"Skolkovo Institute of Science and Technology, Moscow, 121205, Russian\nFederation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"Rizvi S.","year":"2018","unstructured":"Rizvi S.; Khan S.A.; Hallemeier C.L.; Kelley R.K.; Gores G.J.; Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol  2018,15(2),95-111","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","volume":"10","author":"Bouvard V.","year":"2009","unstructured":"Bouvard V.; Baan R.; Straif K.; Grosse Y.; Secretan B.; Ghissassi F.E.; Benbrahim-Tallaa L.; Guha N.; Freeman C.; Galichet L.; Cogliano V.; A review of human carcinogens-Part B: biological agents. Lancet Oncol  2009,10(4),321-322","journal-title":"Lancet Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"Brindley P.J.","year":"2021","unstructured":"Brindley P.J.; Bachini M.; Ilyas S.I.; Khan S.A.; Loukas A.; Sirica A.E.; Teh B.T.; Wongkham S.; Gores G.J.; Cholangiocarcinoma. Nat Rev Dis Primers  2021,7(1),65","journal-title":"Nat Rev Dis Primers"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.18632\/oncotarget.3465","volume":"6","author":"Wang L.J.","year":"2015","unstructured":"Wang L.J.; He C.C.; Sui X.; Cai M.J.; Zhou C.Y.; Ma J.L.; Wu L.; Wang H.; Han S.X.; Zhu Q.; MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget  2015,6(8),5932-5946","journal-title":"Oncotarget"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.3748\/wjg.v11.i48.7625","volume":"11","author":"Mansfield S.D.","year":"2005","unstructured":"Mansfield S.D.; Barakat O.; Charnley R.M.; Jaques B.C.; O\u2019Suilleabhain C.B.; Atherton P.J.; Manas D.; Management of hilar cholangiocarcinoma in the North of England: Pathology, treatment, and outcome. World J Gastroenterol  2005,11(48),7625-7630","journal-title":"World J Gastroenterol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.radonc.2011.05.016","volume":"99","author":"Polistina F.A.","year":"2011","unstructured":"Polistina F.A.; Guglielmi R.; Baiocchi C.; Francescon P.; Scalchi P.; Febbraro A.; Costantin G.; Ambrosino G.; Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol  2011,99(2),120-123","journal-title":"Radiother Oncol"},{"key":"ref=7","first-page":"1469","volume":"18","author":"Goral V.","year":"2017","unstructured":"Goral V.; Cholangiocarcinoma: New Insights. APJCP  2017,18(6),1469-1473","journal-title":"APJCP"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18821\/1028-9984-2015-21-1-11-17","volume":"21","author":"Garin AM","year":"2016","unstructured":"Garin AM; Bazin IS; Morbidity, mortality, long-term outcomes and sequelae of the treatment of cancer patients in different countries of the world. Russ J Oncol  2016,21((1-2)),11-7","journal-title":"Russ J Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e0008421","DOI":"10.1371\/journal.pntd.0008421","volume":"14","author":"Fedorova O.S.","year":"2020","unstructured":"Fedorova O.S.; Fedotova M.M.; Zvonareva O.I.; Mazeina S.V.; Kovshirina Y.V.; Sokolova T.S.; Golovach E.A.; Kovshirina A.E.; Konovalova U.V.; Kolomeets I.L.; Gutor S.S.; Petrov V.A.; Hattendorf J.; Ogorodova L.M.; Odermatt P.; Opisthorchis felineus infection, risks, and morbidity in rural Western Siberia, Russian Federation. PLoS Negl Trop Dis  2020,14(6),e0008421","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-pathmechdis-012418-012818","volume":"14","author":"Ogino S.","year":"2019","unstructured":"Ogino S.; Nowak J.A.; Hamada T.; Milner D.A.; Nishihara R.; Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol  2019,14(1),83-103","journal-title":"Annu Rev Pathol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/j.actatropica.2010.07.006","volume":"120","author":"Sripa B.","year":"2011","unstructured":"Sripa B.; Bethony J.M.; Sithithaworn P.; Kaewkes S.; Mairiang E.; Loukas A.; Mulvenna J.; Laha T.; Hotez P.J.; Brindley P.J.; Opisthorchiasis and opisthorchis-associated cholangiocarcinoma in thailand and laos. Acta Trop  2011,120(Suppl 1),S158-S168","journal-title":"Acta Trop"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13149-017-0544-8","volume":"110","author":"Buisson Y.","year":"2017","unstructured":"Buisson Y.; Control of Opisthorchis viverrini infection for cholangiocarcinoma prevention. Bull Soc Pathol Exot  2017,110(1),61-67","journal-title":"Bull Soc Pathol Exot"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.critrevonc.2008.09.008","volume":"69","author":"Mosconi S.","year":"2009","unstructured":"Mosconi S.; Beretta G.D.; Labianca R.; Zampino M.G.; Gatta G.; Heinemann V.; Cholangiocarcinoma. Crit Rev Oncol Hematol  2009,69(3),259-270","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=14","author":"Heimbach JK","year":"2010","unstructured":"Heimbach JK; Rosen CB; Nagorney DM; Transplantation for hilar cholangiocarcinoma. Surgical Management of Hepatobiliary and Pancreatic Disorders  2010","journal-title":"Surgical Management of Hepatobiliary and Pancreatic Disorders"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"Eckel F.","year":"2007","unstructured":"Eckel F.; Schmid R.M.; Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials. Br J Cancer  2007,96(6),896-902","journal-title":"Br J Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.12659\/MSM.889379","volume":"19","author":"Jha R.K.","year":"2013","unstructured":"Jha R.K.; Noor H.; Jian-Bo Z.; Lin W.; Jha R.K.; Advances in diagnosis and treatment of hilar cholangiocarcinoma \u2013 A review. Med Sci Monit  2013,19,648-656","journal-title":"Med Sci Monit"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/cancers14041026","volume":"14","author":"Pavicevic S.","year":"2022","unstructured":"Pavicevic S.; Reichelt S.; Uluk D.; Lurje I.; Engelmann C.; Modest D.P.; Pelzer U.; Krenzien F.; Raschzok N.; Benzing C.; Sauer I.M.; Stintzing S.; Tacke F.; Sch\u00f6ning W.; Schmelzle M.; Pratschke J.; Lurje G.; Prognostic and predictive molecular markers in cholangiocarcinoma. Cancers  2022,14(4),1026","journal-title":"Cancers"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","volume":"16","author":"Satriano L.","year":"2019","unstructured":"Satriano L.; Lewinska M.; Rodrigues P.M.; Banales J.M.; Andersen J.B.; Metabolic rearrangements in primary liver cancers: Cause and consequences. Nat Rev Gastroenterol Hepatol  2019,16(12),748-766","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14737159.2019.1673162","volume":"19","author":"Intuyod K.","year":"2019","unstructured":"Intuyod K.; Armartmuntree N.; Jusakul A.; Sakonsinsiri C.; Thanan R.; Pinlaor S.; Current omics-based biomarkers for cholangiocarcinoma. Expert Rev Mol Diagn  2019,19(11),997-1005","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","volume":"12","author":"Lee T.","year":"2020","unstructured":"Lee T.; Teng T.Z.J.; Shelat V.G.; Carbohydrate antigen 19-9 - tumor marker: Past, present, and future. World J Gastrointest Surg  2020,12(12),468-490","journal-title":"World J Gastrointest Surg"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/EDE.0000000000000471","volume":"27","author":"Ogino S.","year":"2016","unstructured":"Ogino S.; Nishihara R.; VanderWeele T.J.; Wang M.; Nishi A.; Lochhead P.; Qian Z.R.; Zhang X.; Wu K.; Nan H.; Yoshida K.; Milner D.A.; Chan A.T.; Field A.E.; Camargo C.A.; Williams M.A.; Giovannucci E.L.; The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology  2016,27(4),602-611","journal-title":"Epidemiology"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.05.001","author":"Bertino G","year":"2012","unstructured":"Bertino G; Ardiri A; Malaguarnera M; Malaguarnera G; Bertino N; Calvagno GS; Hepatocellualar carcinoma serum markers. Seminars in oncology  2012","journal-title":"Seminars in oncology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","volume":"50","author":"Levy C.","year":"2005","unstructured":"Levy C.; Lymp J.; Angulo P.; Gores G.J.; Larusso N.; Lindor K.D.; The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci  2005,50(9),1734-1740","journal-title":"Dig Dis Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/0016-5085(95)90462-X","volume":"108","author":"Ramage J.K.","year":"1995","unstructured":"Ramage J.K.; Donaghy A.; Farrant J.M.; Iorns R.; Williams R.; Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology  1995,108(3),865-869","journal-title":"Gastroenterology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.hpb.2019.03.363","volume":"21","author":"Bolm L.","year":"2019","unstructured":"Bolm L.; Petrova E.; Weitz J.; R\u00fcckert F.; Wittel U.A.; Makowiec F.; Lapshyn H.; Bronsert P.; Rau B.M.; Khatkov I.E.; Bausch D.; Keck T.; Wellner U.F.; Distler M.; Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB  2019,21(11),1513-1519","journal-title":"HPB"},{"key":"ref=26","first-page":"7890","volume":"7","author":"Cai W.K.","year":"2014","unstructured":"Cai W.K.; Lin J.J.; He G.H.; Wang H.; Lu J.H.; Yang G.S.; Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol  2014,7(11),7890-7898","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jgh.13059","volume":"31","author":"Lee B.S.","year":"2016","unstructured":"Lee B.S.; Lee S.H.; Son J.H.; Jang D.K.; Chung K.H.; Paik W.H.; Ryu J.K.; Kim Y.T.; Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol  2016,31(2),493-500","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.12659\/MSM.895040","volume":"21","author":"Liang B.","year":"2015","unstructured":"Liang B.; Zhong L.; He Q.; Wang S.; Pan Z.; Wang T.; Zhao Y.; Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: A systematic review and meta-analysis. Med Sci Monit  2015,21,3555-3563","journal-title":"Med Sci Monit"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3748\/wjg.v7.i3.431","volume":"7","author":"Zheng C.X.","year":"2001","unstructured":"Zheng C.X.; Zhan W.H.; Zhao J.Z.; Zheng D.; Wang D.P.; He Y.L.; Zheng Z.Q.; The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol  2001,7(3),431-434","journal-title":"World J Gastroenterol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/2047-783X-15-8-357","volume":"15","author":"Juntermanns B.","year":"2010","unstructured":"Juntermanns B.; Radunz S.; Heuer M.; Hertel S.; Reis H.; Neuhaus J.P.; Vernadakis S.; Trarbach T.; Paul A.; Kaiser G.M.; Tumor markers as a diagnostic key for hilar Cholangiocarcinoma. Eur J Med Res  2010,15(8),357-361","journal-title":"Eur J Med Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6016931","volume":"2019","author":"Fang T.","year":"2019","unstructured":"Fang T.; Wang H.; Wang Y.; Lin X.; Cui Y.; Wang Z.; Clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of cholangiocarcinoma. Dis Markers  2019,2019,1-7","journal-title":"Dis Markers"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.7314\/APJCP.2015.16.8.3451","volume":"16","author":"Li Y.","year":"2015","unstructured":"Li Y.; Li D.J.; Chen J.; Liu W.; Li J.W.; Jiang P.; Zhao X.; Guo F.; Li X.W.; Wang S.G.; Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma. Asian Pac J Cancer Prev  2015,16(8),3451-3455","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cca.2018.02.008","volume":"480","author":"Qiu Y.","year":"2018","unstructured":"Qiu Y.; He J.; Chen X.; Huang P.; Hu K.; Yan H.; The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. Clin Chim Acta  2018,480,186-192","journal-title":"Clin Chim Acta"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/hep.1840100209","volume":"10","author":"Nakanuma Y.","year":"1989","unstructured":"Nakanuma Y.; Sasaki M.; Expression of blood group-related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases. Hepatology  1989,10(2),174-178","journal-title":"Hepatology"},{"key":"ref=35","first-page":"968","volume":"78","author":"Kanai T.","year":"1987","unstructured":"Kanai T.; Hirohashi S.; Upton M.P.; Ino Y.; Shimosato Y.; Expression of Lewis blood group antigens in cancerous and non-cancerous liver. Jpn J Cancer Res  1987,78(9),968-976","journal-title":"Jpn J Cancer Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"528","DOI":"10.21147\/j.issn.1000-9604.2016.05.08","volume":"28","author":"Li F.H.","year":"2009","unstructured":"Li F.H.; Chen X.Q.; Luo H.Y.; Li Y.H.; Wang F.; Qiu M.Z.; Teng K.Y.; Li Z.H.; Xu R.H.; [Prognosis of 84 intrahepatic cholangiocarcinoma patients]. Chin J Cancer  2009,28(5),528-532","journal-title":"Chin J Cancer"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00535-006-1877-z","volume":"41","author":"Miwa S.","year":"2006","unstructured":"Miwa S.; Miyagawa S.; Kobayashi A.; Akahane Y.; Nakata T.; Mihara M.; Kusama K.; Soeda J.; Ogawa S.; Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol  2006,41(9),893-900","journal-title":"J Gastroenterol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(82)90400-7","volume":"31","author":"Moll R.","year":"1982","unstructured":"Moll R.; Franke W.W.; Schiller D.L.; Geiger B.; Krepler R.; The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell  1982,31(1),11-24","journal-title":"Cell"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1083\/jcb.111.2.567","volume":"111","author":"Moll R.","year":"1990","unstructured":"Moll R.; Schiller D.L.; Franke W.W.; Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol  1990,111(2),567-580","journal-title":"J Cell Biol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/sj.bjc.6601851","volume":"90","author":"Pujol J-L.","year":"2004","unstructured":"Pujol J-L.; Molinier O.; Ebert W.; Daur\u00e8s J-P.; Barlesi F.; Buccheri G.; Paesmans M.; Quoix E.; Moro-Sibilot D.; Szturmowicz M.; Br\u00e9chot J-M.; Muley T.; Grenier J.; CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: Results of a meta-analysis in 2063 patients. Br J Cancer  2004,90(11),2097-2105","journal-title":"Br J Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1054\/bjoc.2000.1502","volume":"83","author":"Doweck I.","year":"2000","unstructured":"Doweck I.; Barak M.; Uri N.; Greenberg E.; The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer  2000,83(12),1696-1701","journal-title":"Br J Cancer"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/sj.bjc.6602074","volume":"91","author":"Nakata B.","year":"2004","unstructured":"Nakata B.; Takashima T.; Ogawa Y.; Ishikawa T.; Hirakawa K.; Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer  2004,91(5),873-878","journal-title":"Br J Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10620-014-3472-0","volume":"60","author":"Huang L.","year":"2015","unstructured":"Huang L.; Chen W.; Liang P.; Hu W.; Zhang K.; Shen S.; Chen J.; Zhang Z.; Chen B.; Han Y.; Meng F.; DeMorrow S.; Yin X.; Lai J.; Liang L.; Serum CYFRA 21-1 in biliary tract cancers: A reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma. Dig Dis Sci  2015,60(5),1273-1283","journal-title":"Dig Dis Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1478-3231.2007.01577.x","volume":"27","author":"Itatsu K.","year":"2007","unstructured":"Itatsu K.; Zen Y.; Ohira S.; Ishikawa A.; Sato Y.; Harada K.; Ikeda H.; Sasaki M.; Nimura Y.; Nakanuma Y.; Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int  2007,27(9),1174-1184","journal-title":"Liver Int"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1600-0676.1993.tb00617.x","volume":"13","author":"Van Eyken P.","year":"1993","unstructured":"Van Eyken P.; Desmet V.J.; Cytokeratins and the liver. Liver  1993,13(3),113-122","journal-title":"Liver"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1357-4310(00)01686-5","volume":"6","author":"McCawley L.J.","year":"2000","unstructured":"McCawley L.J.; Matrisian L.M.; Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today  2000,6(4),149-156","journal-title":"Mol Med Today"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1387\/ijdb.041811af","volume":"48","author":"Folgueras A.R.","year":"2004","unstructured":"Folgueras A.R.; Pend\u00e1s A.M.; S\u00e1nchez L.M.; L\u00f3pez-Ot\u00edn C.; Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int J Dev Biol  2004,48(5-6),411-424","journal-title":"Int J Dev Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12032-007-9031-1","volume":"25","author":"Acar A.","year":"2008","unstructured":"Acar A.; Onan A.; Coskun U.; Uner A.; Bagriacik U.; Atalay F.; Unsal D.K.; Guner H.; Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med Oncol  2008,25(3),279-283","journal-title":"Med Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1373\/clinchem.2007.090837","volume":"54","author":"Sarkissian G.","year":"2008","unstructured":"Sarkissian G.; Fergelot P.; Lamy P.J.; Patard J.J.; Culine S.; Jouin P.; Rioux-Leclercq N.; Darbouret B.; Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem  2008,54(3),574-581","journal-title":"Clin Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.3748\/wjg.v16.i37.4697","volume":"16","author":"Leelawat K.","year":"2010","unstructured":"Leelawat K.; Narong S.; Wannaprasert J.; Ratanashu-ek T.; Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol  2010,16(37),4697-4703","journal-title":"World J Gastroenterol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.toxlet.2013.10.030","volume":"224","author":"Yang M.","year":"2014","unstructured":"Yang M.; Ramachandran A.; Yan H.M.; Woolbright B.L.; Copple B.L.; Fickert P.; Trauner M.; Jaeschke H.; Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. Toxicol Lett  2014,224(2),186-195","journal-title":"Toxicol Lett"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"E856","DOI":"10.1073\/pnas.1316447111","volume":"111","author":"Kourepini E.","year":"2014","unstructured":"Kourepini E.; Aggelakopoulou M.; Alissafi T.; Paschalidis N.; Simoes D.C.M.; Panoutsakopoulou V.; Osteopontin expression by CD103  dendritic cells drives intestinal inflammation. Proc Natl Acad Sci  2014,111(9),E856-E865","journal-title":"Proc Natl Acad Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/358218","volume":"2014","author":"Marcondes M.C.G.","year":"2014","unstructured":"Marcondes M.C.G.; Ojakian R.; Bortell N.; Flynn C.; Conti B.; Fox H.S.; Osteopontin expression in the brain triggers localized inflammation and cell death when immune cells are activated by pertussis toxin. Mediators Inflamm  2014,2014,1-12","journal-title":"Mediators Inflamm"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10120-015-0495-y","volume":"19","author":"Di Bartolomeo M.","year":"2016","unstructured":"Di Bartolomeo M.; Pietrantonio F.; Pellegrinelli A.; Martinetti A.; Mariani L.; Daidone M.G.; Bajetta E.; Pelosi G.; de Braud F.; Floriani I.; Miceli R.; Osteopontin, E-cadherin, and \u03b2-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer  2016,19(2),412-420","journal-title":"Gastric Cancer"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jnci\/94.7.513","volume":"94","author":"Agrawal D.","year":"2002","unstructured":"Agrawal D.; Chen T.; Irby R.; Quackenbush J.; Chambers A.F.; Szabo M.; Cantor A.; Coppola D.; Yeatman T.J.; Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst  2002,94(7),513-521","journal-title":"J Natl Cancer Inst"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/CBM-160617","volume":"17","author":"Rychl\u00edkov\u00e1 J.","year":"2016","unstructured":"Rychl\u00edkov\u00e1 J.; Vecka M.; J\u00e1chymov\u00e1 M.; Mac\u00e1\u0161ek J.; Hrab\u00e1k P.; Zeman M.; V\u00e1vrov\u00e1 L.; \u0158oupal J.; Krechler T.; \u00e1k A.; Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomark  2016,17(1),55-65","journal-title":"Cancer Biomark"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MPA.0b013e31825e354d","volume":"42","author":"Poruk K.E.","year":"2013","unstructured":"Poruk K.E.; Firpo M.A.; Scaife C.L.; Adler D.G.; Emerson L.L.; Boucher K.M.; Mulvihill S.J.; Serum osteopontin and TIMP-1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas  2013,42(2),193","journal-title":"Pancreas"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.24703","volume":"55","author":"Shang S.","year":"2012","unstructured":"Shang S.; Plymoth A.; Ge S.; Feng Z.; Rosen H.R.; Sangrajrang S.; Hainaut P.; Marrero J.A.; Beretta L.; Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology  2012,55(2),483-490","journal-title":"Hepatology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jhep.2017.06.020","volume":"67","author":"Loosen S.H.","year":"2017","unstructured":"Loosen S.H.; Roderburg C.; Kauertz K.L.; Pombeiro I.; Leyh C.; Benz F.; Vucur M.; Longerich T.; Koch A.; Braunschweig T.; Ulmer T.F.; Heidenhain C.; Tacke F.; Binneb\u00f6sel M.; Schmeding M.; Trautwein C.; Neumann U.P.; Luedde T.; Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J Hepatol  2017,67(4),749-757","journal-title":"J Hepatol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"582","DOI":"10.21037\/hbsn.2019.03.14","volume":"8","author":"Zhou K.Q.","year":"2019","unstructured":"Zhou K.Q.; Liu W.F.; Yang L.X.; Sun Y.F.; Hu J.; Chen F.Y.; Zhou C.; Zhang X.Y.; Peng Y.F.; Yu L.; Zhou J.; Fan J.; Wang Z.; Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr  2019,8(6),582-596","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.30319","volume":"70","author":"Ba\u00f1ales Asurmendi JM","year":"2019","unstructured":"Ba\u00f1ales Asurmendi JM; I\u00f1arrairaegui M; Arbelaiz Cossio A; Milkiewicz P; Muntan\u00e9 J; Mu\u00f1oz Bellvis L; La Casta A; Gonzaz LM; Arretxe Oliden E; Alonso C; Mart\u00ednez Arranz I; Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatolog  2019,70(2),547-562","journal-title":"Hepatolog"},{"key":"ref=62","first-page":"S1524","author":"Kei A.","year":"2015","unstructured":"Kei A.; Prognostic impact of peritumoral IL-17-positive cells and IL-17 axis in patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol  2015,S1524-S1531","journal-title":"Ann Surg Oncol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.jhepr.2020.100080","volume":"2","author":"Loosen S.H.","year":"2020","unstructured":"Loosen S.H.; Breuer A.; Tacke F.; Kather J.N.; Gorgulho J.; Alizai P.H.; Bednarsch J.; Roeth A.A.; Lurje G.; Schmitz S.M.; Brozat J.F.; Paffenholz P.; Vucur M.; Ritz T.; Koch A.; Trautwein C.; Ulmer T.F.; Roderburg C.; Longerich T.; Neumann U.P.; Luedde T.; Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer. JHEP Reports  2020,2(2),100080","journal-title":"JHEP Reports"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3748\/wjg.v18.i3.244","volume":"18","author":"Thummarati P.","year":"2012","unstructured":"Thummarati P.; Wijitburaphat S.; Prasopthum A.; Menakongka A.; Sripa B.; Tohtong R.; Suthiphongchai T.; High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol  2012,18(3),244-250","journal-title":"World J Gastroenterol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.clinbiochem.2014.01.030","volume":"47","author":"Grunnet M.","year":"2014","unstructured":"Grunnet M.; Christensen I.J.; Lassen U.; Jensen L.H.; Lydolph M.; Lund I.K.; Thurison T.; H\u00f8yer-Hansen G.; Mau-S\u00f8rensen M.; Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. Clin Biochem  2014,47(7-8),599-604","journal-title":"Clin Biochem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/17474124.2021.1912591","volume":"15","author":"Lang S.A.","year":"2021","unstructured":"Lang S.A.; Bednarsch J.; Joechle K.; Amygdalos I.; Czigany Z.; Heij L.; Ulmer T.F.; Neumann U.P.; Prognostic biomarkers for cholangiocarcinoma (CCA): State of the art. Expert Rev Gastroenterol Hepatol  2021,15(5),497-510","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2017.04.043","volume":"153","author":"Severino V.","year":"2017","unstructured":"Severino V.; Dumonceau J.M.; Delhaye M.; Moll S.; Annessi-Ramseyer I.; Robin X.; Frossard J.L.; Farina A.; Extracellular vesicles in bile as markers of malignant biliary stenoses. Gastroenterology  2017,153(2),495-504.e8","journal-title":"Gastroenterology"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.3390\/cancers13133222","volume":"13","author":"Rodrigues P.M.","year":"2021","unstructured":"Rodrigues P.M.; Vogel A.; Arrese M.; Balderramo D.C.; Valle J.W.; Banales J.M.; Next-generation biomarkers for cholangiocarcinoma. Cancers  2021,13(13),3222","journal-title":"Cancers"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"14744","DOI":"10.18632\/oncotarget.4539","volume":"6","author":"Brandi G.","year":"2015","unstructured":"Brandi G.; Farioli A.; Astolfi A.; Biasco G.; Tavolari S.; Genetic heterogeneity in cholangiocarcinoma: A major challenge for targeted therapies. Oncotarget  2015,6(17),14744-14753","journal-title":"Oncotarget"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/liv.14090","volume":"39","author":"Macias R.I.R.","year":"2019","unstructured":"Macias R.I.R.; Kornek M.; Rodrigues P.M.; Paiva N.A.; Castro R.E.; Urban S.; Pereira S.P.; Cadamuro M.; Rupp C.; Loosen S.H.; Luedde T.; Banales J.M.; Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int  2019,39(S1),108-122","journal-title":"Liver Int"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","volume":"142","author":"Andersen J.B.","year":"2012","unstructured":"Andersen J.B.; Spee B.; Blechacz B.R.; Avital I.; Komuta M.; Barbour A.; Conner E.A.; Gillen M.C.; Roskams T.; Roberts L.R.; Factor V.M.; Thorgeirsson S.S.; Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology  2012,142(4),1021-1031.e15","journal-title":"Gastroenterology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2017.09.005","volume":"86","author":"Ghidini M.","year":"2017","unstructured":"Ghidini M.; Cascione L.; Carotenuto P.; Lampis A.; Trevisani F.; Previdi M.C.; Hahne J.C.; Said-Huntingford I.; Raj M.; Zerbi A.; Mescoli C.; Cillo U.; Rugge M.; Roncalli M.; Torzilli G.; Rimassa L.; Santoro A.; Valeri N.; Fassan M.; Braconi C.; Characterisation of the immune-related transcriptome in resected biliary tract cancers. Eur J Cancer  2017,86,158-165","journal-title":"Eur J Cancer"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/OTT.S141476","volume":"10","author":"Huang D.W.","year":"2017","unstructured":"Huang D.W.; Huang M.; Lin X.S.; Huang Q.; CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. OncoTargets Ther  2017,10,3817-3825","journal-title":"OncoTargets Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737140.2018.1467760","volume":"18","author":"Saengboonmee C.","year":"2018","unstructured":"Saengboonmee C.; Sawanyawisuth K.; Chamgramol Y.; Wongkham S.; Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Rev Anticancer Ther  2018,18(6),579-592","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jss.2014.05.017","volume":"192","author":"Sulpice L","year":"2014","unstructured":"Sulpice L; Rayar M; Turlin B; Boucher E; Bellaud P; Desille M; Meunier B; Cl\u00e9ment B; Boudjema K; Coulouarn C; Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma. J Surg Res  2014,192(1),117-23","journal-title":"J Surg Res"},{"key":"ref=76","first-page":"6157","volume":"7","author":"Sun Q.","year":"2014","unstructured":"Sun Q.; Zhao C.; Xia L.; He Z.; Lu Z.; Liu C.; Jia M.; Wang J.; Niu J.; High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma. Int J Clin Exp Pathol  2014,7(9),6157-6164","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.7314\/APJCP.2015.16.9.3697","volume":"16","author":"Tongtawee T.","year":"2015","unstructured":"Tongtawee T.; Kaewpitoon S.J.; Loyd R.; Chanvitan S.; Leelawat K.; Praditpol N.; Jujinda S.; Kaewpitoon N.; High expression of matrix metalloproteinase-11 indicates poor prognosis in human cholangiocarcinoma. Asian Pac J Cancer Prev  2015,16(9),3697-3701","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.3748\/wjg.v11.i32.4939","volume":"11","author":"Boonla C.","year":"2005","unstructured":"Boonla C.; Sripa B.; Thuwajit P.; Cha-On U.; Puapairoj A.; Miwa M.; Wongkham S.; MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol  2005,11(32),4939-4946","journal-title":"World J Gastroenterol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ejso.2015.07.006","volume":"41","author":"Abe T.","year":"2015","unstructured":"Abe T.; Amano H.; Shimamoto F.; Hattori M.; Kuroda S.; Kobayashi T.; Tashiro H.; Ohdan H.; Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy. Eur J Surg Oncol  2015,41(11),1515-1521","journal-title":"Eur J Surg Oncol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1096\/fasebj.8.15.8001744","volume":"8","author":"Javitt N.B.","year":"1994","unstructured":"Javitt N.B.; Bile acid synthesis from cholesterol: Regulatory and auxiliary pathways. FASEB J  1994,8(15),1308-1311","journal-title":"FASEB J"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12986-022-00677-1","volume":"19","author":"Wang Y.","year":"2022","unstructured":"Wang Y.; Lu J.; Wen N.; Nie G.; Peng D.; Xiong X.; Cheng N.; Li B.; The role of diet and nutrition related indicators in biliary diseases: An umbrella review of systematic review and meta-analysis. Nutr Metab  2022,19(1),51","journal-title":"Nutr Metab"},{"key":"ref=82","first-page":"2426","volume":"42","author":"Cameron R.G.","year":"1982","unstructured":"Cameron R.G.; Imaida K.; Tsuda H.; Ito N.; Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res  1982,42(6),2426-2428","journal-title":"Cancer Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/carcin\/23.5.885","volume":"23","author":"Oyama K.","year":"2002","unstructured":"Oyama K.; Shiota G.; Ito H.; Murawaki Y.; Kawasaki H.; Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis  2002,23(5),885-892","journal-title":"Carcinogenesis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.freeradbiomed.2005.07.005","volume":"39","author":"Komichi D.","year":"2005","unstructured":"Komichi D.; Tazuma S.; Nishioka T.; Hyogo H.; Chayama K.; Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radic Biol Med  2005,39(11),1418-1427","journal-title":"Free Radic Biol Med"},{"key":"ref=85","author":"Trauner M.","year":"2007","unstructured":"Trauner M.; Fickert P.; Wagner M.; MDR3 (ABCB4) defects: A paradigm for the genetics of adult cholestatic syndromes. Seminars in liver disease  2007","journal-title":"Seminars in liver disease"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.3748\/wjg.15.3329","volume":"15","author":"Bernstein H.","year":"2009","unstructured":"Bernstein H.; Bernstein C.; Payne C.M.; Dvorak K.; Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol  2009,15(27),3329-3340","journal-title":"World J Gastroenterol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000226812","volume":"47","author":"Kinami Y.","year":"1990","unstructured":"Kinami Y.; Ashida Y.; Seto K.; Takashima S.; Kita I.; Influence of incomplete bile duct obstruction on the occurrence of cholangiocarcinoma induced by diisopropanolnitrosamine in hamsters. Oncology  1990,47(2),170-176","journal-title":"Oncology"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000227146","volume":"50","author":"Kinami Y.","year":"1993","unstructured":"Kinami Y.; Ashida Y.; Gotoda H.; Seto K.; Kojima Y.; Takashima S.; Promoting effects of bile acid load on the occurrence of cholangiocarcinoma induced by diisopropanolnitrosamine in hamsters. Oncology  1993,50(1),46-51","journal-title":"Oncology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2302\/kjm.40.118","volume":"40","author":"Funabiki T.","year":"1991","unstructured":"Funabiki T.; Sugiue K.; Matsubara T.; Amano H.; Ochiai M.; Bile acids and biliary carcinoma in pancreaticobiliary maljunction. Keio J Med  1991,40(3),118-122","journal-title":"Keio J Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3349\/ymj.2006.47.6.817","volume":"47","author":"Park J.Y.","year":"2006","unstructured":"Park J.Y.; Park B.K.; Ko J.S.; Bang S.; Song S.Y.; Chung J.B.; Bile acid analysis in biliary tract cancer. Yonsei Med J  2006,47(6),817-825","journal-title":"Yonsei Med J"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/02841850802220092","volume":"49","author":"Albiin N.","year":"2008","unstructured":"Albiin N.; Smith I.C.P.; Arnelo U.; Lindberg B.; Bergquist A.; Dolenko B.; Bryksina N.; Bezabeh T.; Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol  2008,49(8),855-862","journal-title":"Acta Radiol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1477-2574.2010.00185.x","volume":"12","author":"Sharif A.W.","year":"2010","unstructured":"Sharif A.W.; Williams H.R.T.; Lampejo T.; Khan S.A.; Bansi D.S.; Westaby D.; Thillainayagam A.V.; Thomas H.C.; Cox I.J.; Taylor-Robinson S.D.; Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB  2010,12(6),396-402","journal-title":"HPB"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3892\/mmr.2014.2973","volume":"11","author":"Xu X.","year":"2015","unstructured":"Xu X.; Cheng S.; Ding C.; Lv Z.; Chen D.; Wu J.; Zheng S.; Identification of bile biomarkers of biliary tract cancer through a liquid chromatography\/mass spectrometry-based metabolomic method. Mol Med Rep  2015,11(3),2191-2198","journal-title":"Mol Med Rep"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0092-8674(00)81370-7","volume":"87","author":"van Helvoort A.","year":"1996","unstructured":"van Helvoort A.; Smith A.J.; Sprong H.; Fritzsche I.; Schinkel A.H.; Borst P.; van Meer G.; MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell  1996,87(3),507-517","journal-title":"Cell"},{"key":"ref=95","first-page":"1237","volume":"145","author":"Mauad T.H.","year":"1994","unstructured":"Mauad T.H.; van Nieuwkerk C.M.; Dingemans K.P.; Smit J.J.; Schinkel A.H.; Notenboom R.G.; van den Bergh Weerman M.A.; Verkruisen R.P.; Groen A.K.; Oude Elferink R.P.; Van Der Valk M.A.; Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol  1994,145(5),1237-1245","journal-title":"Am J Pathol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","volume":"366","author":"Khan S.A.","year":"2005","unstructured":"Khan S.A.; Thomas H.C.; Davidson B.R.; Taylor-Robinson S.D.; Cholangiocarcinoma. Lancet  2005,366(9493),1303-1314","journal-title":"Lancet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13167-018-0147-5","volume":"9","author":"Lee J.H.","year":"2018","unstructured":"Lee J.H.; Yu S.E.; Kim K.H.; Yu M.H.; Jeong I.H.; Cho J.Y.; Park S.J.; Lee W.J.; Han S.S.; Kim T.H.; Hong E.K.; Woo S.M.; Yoo B.C.; Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: A useful tool for innovative screening programs and predictive strategies in healthcare. EPMA J  2018,9(3),287-297","journal-title":"EPMA J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.1038\/s41598-018-29445-z","volume":"8","author":"Song W.S.","year":"2018","unstructured":"Song W.S.; Park H.M.; Ha J.M.; Shin S.G.; Park H.G.; Kim J.; Zhang T.; Ahn D.H.; Kim S.M.; Yang Y.H.; Jeong J.H.; Theberge A.B.; Kim B.G.; Lee J.K.; Kim Y.G.; Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma. Sci Rep  2018,8(1),11088","journal-title":"Sci Rep"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ajg.2014.60","volume":"109","author":"Navaneethan U","year":"2014","unstructured":"Navaneethan U; Gutierrez NG; Venkatesh PG; Jegadeesan R; Zhang R; Jang S; Sanaka MR; Vargo JJ; Parsi MA; Feldstein AE; Stevens T; Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: A single-blinded pilot study. J Am Coll Gastroenterol  2014,109(6),895-902","journal-title":"J Am Coll Gastroenterol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1158\/0008-5472.CAN-08-2133","volume":"68","author":"Alpini G.","year":"2008","unstructured":"Alpini G.; Invernizzi P.; Gaudio E.; Venter J.; Kopriva S.; Bernuzzi F.; Onori P.; Franchitto A.; Coufal M.; Frampton G.; Alvaro D.; Lee S.P.; Marzioni M.; Benedetti A.; DeMorrow S.; Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res  2008,68(22),9184-9193","journal-title":"Cancer Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1074\/mcp.T400015-MCP200","volume":"4","author":"Mayya V.","year":"2005","unstructured":"Mayya V.; Rezaul K.; Cong Y.S.; Han D.; Systematic comparison of a two-dimensional ion trap and a three-dimensional ion trap mass spectrometer in proteomics. Mol Cell Proteomics  2005,4(2),214-223","journal-title":"Mol Cell Proteomics"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/cncr.20469","volume":"101","author":"Koopmann J.","year":"2004","unstructured":"Koopmann J.; Thuluvath P.J.; Zahurak M.L.; Kristiansen T.Z.; Pandey A.; Schulick R.; Argani P.; Hidalgo M.; Iacobelli S.; Goggins M.; Maitra A.; Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer  2004,101(7),1609-1615","journal-title":"Cancer"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e47476","DOI":"10.1371\/journal.pone.0047476","volume":"7","author":"Shen J.","year":"2012","unstructured":"Shen J.; Wang W.; Wu J.; Feng B.; Chen W.; Wang M.; Tang J.; Wang F.; Cheng F.; Pu L.; Tang Q.; Wang X.; Li X.; Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS One  2012,7(10),e47476","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317705764","volume":"39","author":"Laohaviroj M.","year":"2017","unstructured":"Laohaviroj M.; Potriquet J.; Jia X.; Suttiprapa S.; Chamgramol Y.; Pairojkul C.; Sithithaworn P.; Mulvenna J.; Sripa B.; A comparative proteomic analysis of bile for biomarkers of cholangiocarcinoma. Tumour Biol  2017,39(6)","journal-title":"Tumour Biol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41598-021-81023-y","volume":"11","author":"Ikeda C.","year":"2021","unstructured":"Ikeda C.; Haga H.; Makino N.; Inuzuka T.; Kurimoto A.; Ueda T.; Matsuda A.; Kakizaki Y.; Ishizawa T.; Kobayashi T.; Sugahara S.; Tsunoda M.; Suda K.; Ueno Y.; Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma. Sci Rep  2021,11(1),1195","journal-title":"Sci Rep"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2147\/CMAR.S158155","volume":"10","author":"Sun C.","year":"2018","unstructured":"Sun C.; Zhu J.; Wu B.; Chen J.; Zhu Z.; Cai P.; Guo W.; Gu Z.; Wang J.; Huang S.; Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: A systematic review and meta-analysis. Cancer Manag Res  2018,10,2125-2139","journal-title":"Cancer Manag Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.clinre.2016.10.007","volume":"41","author":"Zhou J.","year":"2017","unstructured":"Zhou J.; Liu Z.; Yang S.; Li X.; Identification of microRNAs as biomarkers for cholangiocarcinoma detection: A diagnostic meta-analysis. Clin Res Hepatol Gastroenterol  2017,41(2),156-162","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.dld.2016.07.006","volume":"48","author":"Liang Z.","year":"2016","unstructured":"Liang Z.; Liu X.; Zhang Q.; Wang C.; Zhao Y.; Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis  2016,48(10),1227-1232","journal-title":"Dig Liver Dis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e0210944","DOI":"10.1371\/journal.pone.0210944","volume":"14","author":"Loosen S.H.","year":"2019","unstructured":"Loosen S.H.; Lurje G.; Wiltberger G.; Vucur M.; Koch A.; Kather J.N.; Paffenholz P.; Tacke F.; Ulmer F.T.; Trautwein C.; Luedde T.; Neumann U.P.; Roderburg C.; Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. PLoS One  2019,14(1),e0210944","journal-title":"PLoS One"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2174\/1389450116666150223121508","volume":"18","author":"Marin J.J.G.","year":"2017","unstructured":"Marin J.J.G.; Lozano E.; Briz O.; Al-Abdulla R.; Serrano M.A.; Macias R.I.R.; Molecular bases of chemoresistance in cholangiocarcinoma. Curr Drug Targets  2017,18(8),889-900","journal-title":"Curr Drug Targets"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e23397","DOI":"10.1002\/jcla.23397","volume":"34","author":"Salem P.E.S.","year":"2020","unstructured":"Salem P.E.S.; Ghazala R.A.; El Gendi A.M.; Emara D.M.; Ahmed N.M.; The association between circulating MicroRNA-150 level and cholangiocarcinoma. J Clin Lab Anal  2020,34(11),e23397","journal-title":"J Clin Lab Anal"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2004.11.005","volume":"326","author":"Zhang G.H.","year":"2004","unstructured":"Zhang G.H.; Cong A.R.; Xu G.B.; Li C.B.; Yang R.F.; Xia T.A.; An enzymatic cycling method for the determination of serum total bile acids with recombinant 3\u03b1-hydroxysteroid dehydrogenase. Biochem Biophys Res Commun  2004,326(1),87-92","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0039-128X(02)00036-3","volume":"67","author":"Kobayashi N.","year":"2002","unstructured":"Kobayashi N.; Katsumata H.; Uto Y.; Goto J.; Niwa T.; Kobayashi K.; Mizuuchi Y.; A monoclonal antibody-based enzyme-linked immunosorbent assay of glycolithocholic acid sulfate in human urine for liver function test. Steroids  2002,67(10),827-833","journal-title":"Steroids"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jpba.2010.05.028","volume":"53","author":"Ijare O.B.","year":"2010","unstructured":"Ijare O.B.; Bezabeh T.; Albiin N.; Bergquist A.; Arnelo U.; Lindberg B.; Smith I.C.P.; Simultaneous quantification of glycine- and taurine-conjugated bile acids, total bile acids, and choline-containing phospholipids in human bile using 1H NMR spectroscopy. J Pharm Biomed Anal  2010,53(3),667-673","journal-title":"J Pharm Biomed Anal"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1002\/jssc.200900879","volume":"33","author":"Oni\u015for C.","year":"2010","unstructured":"Oni\u015for C.; Po\u0161a M.; Kevre\u0161an S.; Kuhajda K.; S\u00e2rbu C.; Estimation of chromatographic lipophilicity of bile acids and their derivatives by reversed-phase thin layer chromatography. J Sep Sci  2010,33(20),3110-3118","journal-title":"J Sep Sci"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0021-9673(01)00726-9","volume":"917","author":"S\u00e2rbu C.","year":"2001","unstructured":"S\u00e2rbu C.; Kuhajda K.; Kevresan S.; Evaluation of the lipophilicity of bile acids and their derivatives by thin-layer chromatography and principal component analysis. J Chromatogr A  2001,917(1-2),361-366","journal-title":"J Chromatogr A"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.biochi.2012.09.015","volume":"95","author":"Matysik S.","year":"2013","unstructured":"Matysik S.; Schmitz G.; Application of gas chromatography-triple quadrupole mass spectrometry to the determination of sterol components in biological samples in consideration of the ionization mode. Biochimie  2013,95(3),489-495","journal-title":"Biochimie"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/jssc.201500139","volume":"38","author":"Shi Y.","year":"2015","unstructured":"Shi Y.; Xiong J.; Sun D.; Liu W.; Wei F.; Ma S.; Lin R.; Simultaneous quantification of the major bile acids in artificial calculus bovis by high-performance liquid chromatography with precolumn derivatization and its application in quality control. J Sep Sci  2015,38(16),2753-2762","journal-title":"J Sep Sci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1194\/jlr.D047506","volume":"55","author":"Kakiyama G.","year":"2014","unstructured":"Kakiyama G.; Muto A.; Takei H.; Nittono H.; Murai T.; Kurosawa T.; Hofmann A.F.; Pandak W.M.; Bajaj J.S.; A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: Validation by GC-MS and LC-MS. J Lipid Res  2014,55(5),978-990","journal-title":"J Lipid Res"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/diagnostics10070462","volume":"10","author":"Danese E.","year":"2020","unstructured":"Danese E.; Negrini D.; Pucci M.; De Nitto S.; Ambrogi D.; Donzelli S.; Lievens P.M.J.; Salvagno G.L.; Lippi G.; Bile acids quantification by liquid chromatography\u2013tandem mass spectrometry: Method validation, reference range, and interference study. Diagnostics  2020,10(7),462","journal-title":"Diagnostics"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.chroma.2014.10.064","volume":"1371","author":"John C.","year":"2014","unstructured":"John C.; Werner P.; Worthmann A.; Wegner K.; T\u00f6dter K.; Scheja L.; Rohn S.; Heeren J.; Fischer M.; A liquid chromatography-tandem mass spectrometry-based method for the simultaneous determination of hydroxy sterols and bile acids. J Chromatogr A  2014,1371,184-195","journal-title":"J Chromatogr A"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"7799","DOI":"10.1007\/s00216-014-8230-9","volume":"406","author":"J\u00e4ntti S.E.","year":"2014","unstructured":"J\u00e4ntti S.E.; Kivilompolo M.; \u00d6hrnberg L.; Pietil\u00e4inen K.H.; Nygren H.; Ore\u0161i\u010d M.; Hy\u00f6tyl\u00e4inen T.; Quantitative profiling of bile acids in blood, adipose tissue, intestine, and gall bladder samples using ultra high performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem  2014,406(30),7799-7815","journal-title":"Anal Bioanal Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"826740","DOI":"10.3389\/fphys.2022.826740","volume":"13","author":"Zhao X.","year":"2022","unstructured":"Zhao X.; Liu Z.; Sun F.; Yao L.; Yang G.; Wang K.; Bile acid detection techniques and bile acid-related diseases. Front Physiol  2022,13,826740","journal-title":"Front Physiol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11745-002-1005-0","volume":"37","author":"Perwaiz S.","year":"2002","unstructured":"Perwaiz S.; Mignault D.; Tuchweber B.; Yousef I.M.; Rapid and improved method for the determination of bile acids in human feces using MS. Lipids  2002,37(11),1093-1100","journal-title":"Lipids"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jpba.2011.03.035","volume":"55","author":"Huang J.","year":"2011","unstructured":"Huang J.; Bathena S.P.R.; Csanaky I.L.; Alnouti Y.; Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC-MS\/MS. J Pharm Biomed Anal  2011,55(5),1111-1119","journal-title":"J Pharm Biomed Anal"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680266290367240130054142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/226594\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680266290367240130054142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T06:13:37Z","timestamp":1714630417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/226594\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":125,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115680266290367240130054142","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}